What is the role and safety profile of SGLT2 inhibitors in heart failure?

• A. They have no HF benefit.
• B. They worsen volume status significantly and are rarely used.
• C. Improve outcomes; monitor for genitourinary infections and volume status; generally well tolerated.
• D. They replace loop diuretics in all HF patients.

Answer: (C)

SGLT2 inhibitors improve outcomes in heart failure, reducing hospitalizations and cardiovascular death in patients with both reduced and preserved ejection fraction, and they also offer renal and diuretic-like benefits beyond glucose lowering. They are used as part of standard heart failure therapy and can be continued alongside other treatments, with possible reductions in loop diuretic needs as fluid status improves in some patients. The safety profile is notable for a risk of genitourinary infections due to glucosuria and for volume depletion or hypotension, so it’s important to monitor hydration status, blood pressure, and kidney function after starting or adjusting therapy. They are generally well tolerated and are not a blanket replacement for loop diuretics in all heart failure patients. Overall, they improve outcomes with manageable safety concerns—genitourinary infections and volume status—under careful monitoring.